Search Results - "Abunimeh, M"

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III) by Shafran, S. D., Shaw, D., Charafeddine, M., Agarwal, K., Foster, G. R., Abunimeh, M., Pilot‐Matias, T., Pothacamury, R. K., Fu, B., Cohen, E., Cohen, D. E., Gane, E.

“…Summary The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) ± ribavirin (RBV) in…”
Get full text

Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1–6 infection by Persico, M., Flisiak, R., Abunimeh, M., Sise, M., Park, J.Y., Kaskas, M., Bruchfeld, A., Wörns, M.-A., Aglitti, A., Xue, Z., Rullman, J., Pocalla, A., Lawitz, E.

Get full text

Epigenetic reprogramming in hepatitis C virus-induced liver fibrosis: DNA methylation as a biomarker to identify susceptibility by Vasanthakumar, A, Davis, J.W, Idler, K, Dilmukhametova, E, Hazelwood, L, Abunimeh, M, Dorr, P, Charafeddine, M, Cohen, D.E, England, S, Waring, J

Get full text

Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis by Mantry, P, Reddy, R, Cohen, E, Everson, G, Ramji, A, Zeuzem, S, Gordon, S, Yoshida, E, Sherman, M, Balart, L, Baumgarten, A, Lee, S, Fredrick, L.M, Abunimeh, M, Cohen, D.E, Shulman, N.S, Wilson, J

Get full text

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study by Poordad, F, Bennett, M, Sepe, T.E, Cohen, E, Reindollar, R.W, Everson, G, Phillips, R.W, Siddique, A, Sullivan, J.G, Box, T.D, Fu, B, Pilot-Matias, T, Abunimeh, M, Cohen, D.E, Younes, Z

Get full text

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study by Pockros, P.J, Reddy, K.R, Mantry, P.S, Cohen, E, Bennett, M, Sulkowski, M.S, Bernstein, D, Podsadecki, T, Cohen, D, Shulman, N.S, Wang, D, Khatri, A, Abunimeh, M, Lawitz, E

Get full text

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection by Lawitz, Eric, Flisiak, Robert, Abunimeh, Manal, Sise, Meghan E., Park, Jun Y., Kaskas, Marwan, Bruchfeld, Annette, Wörns, Marcus‐Alexander, Aglitti, Andrea, Zamor, Philippe J., Xue, Zhenyi, Schnell, Gretja, Jalundhwala, Yash J., Porcalla, Ariel, Mensa, Federico J., Persico, Marcello

“…Background and Aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end‐stage renal…”
Get full text

THU-363 - Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1–6 infection by Persico, M., Flisiak, R., Abunimeh, M., Sise, M., Park, J.Y., Kaskas, M., Bruchfeld, A., Wörns, M.-A., Aglitti, A., Xue, Z., Rullman, J., Pocalla, A., Lawitz, E.

Get full text

THU-023 - DNA methylation profiling of hepatitis C virus patients treated with direct acting antivirals identifies consistent methylation changes in livers and blood by Vasanthakumar, A., Quarless, D., Dilmukhametova, E., Abunimeh, M., Konefal, C., Abel, S., Idler, K., Lauer, G., Kim, A., Chung, R., Cohen, D., Davis, J.W., Dumas, E., Waring, J.F.

Get full text

DNA methylation profiling of hepatitis C virus patients treated with direct acting antivirals identifies consistent methylation changes in livers and blood by Vasanthakumar, A., Quarless, D., Dilmukhametova, E., Abunimeh, M., Konefal, C., Abel, S., Idler, K., Lauer, G., Kim, A., Chung, R., Cohen, D., Davis, J.W., Dumas, E., Waring, J.F.

Get full text

THU-192 - Epigenetic reprogramming in hepatitis C virus-induced liver fibrosis: DNA methylation as a biomarker to identify susceptibility by Vasanthakumar, A., Davis, J.W., Idler, K., Dilmukhametova, E., Hazelwood, L., Abunimeh, M., Dorr, P., Charafeddine, M., Cohen, D.E., England, S., Waring, J.

Get full text

SAT-251 - Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis by Mantry, P., Reddy, R., Cohen, E., Everson, G., Ramji, A., Zeuzem, S., Gordon, S., Yoshida, E., Sherman, M., Balart, L., Baumgarten, A., Lee, S., Fredrick, L.M., Abunimeh, M., Cohen, D.E., Shulman, N.S., Wilson, J.

Get full text

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens by Vasanthakumar, Aparna, Davis, Justin W, Abunimeh, Manal, Söderholm, Jonas, Zha, Jiuhong, Dumas, Emily O, Cohen, Daniel E, Waring, Jeffrey F, Lagging, Martin

“…Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic…”
Get full text

SAT-156 - Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study by Poordad, F., Bennett, M., Sepe, T.E., Cohen, E., Reindollar, R.W., Everson, G., Phillips, R.W., Siddique, A., Sullivan, J.G., Box, T.D., Fu, B., Pilot-Matias, T., Abunimeh, M., Cohen, D.E., Younes, Z.

Get full text